Zynyz Interactions
There are 596 drugs known to interact with Zynyz (retifanlimab), along with 4 disease interactions. Of the total drug interactions, 3 are major, and 592 are moderate.
- View all 596 medications that may interact with Zynyz
- View Zynyz disease interactions (4)
Most frequently checked interactions
View interaction reports for Zynyz (retifanlimab) and the medicines listed below.
- Actimmune (interferon gamma-1b)
- Adcetris (brentuximab)
- Adcirca (tadalafil)
- Addyi (flibanserin)
- Adzynma (apadamtase alfa, recombinant)
- Aimovig (erenumab)
- albuterol
- Alhemo (concizumab)
- Altuviiio (antihemophilic factor)
- Alyftrek (deutivacaftor / tezacaftor / vanzacaftor)
- ambrisentan
- amlodipine
- Amondys 45 (casimersen)
- Amvuttra (vutrisiran)
- Andembry (garadacimab)
- apremilast
- Attruby (acoramidis)
- Aubagio (teriflunomide)
- Augtyro (repotrectinib)
- Austedo XR (deutetrabenazine)
- Bafiertam (monomethyl fumarate)
- Benlysta (belimumab)
- Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide)
- Bimzelx (bimekizumab)
- Blenrep (belantamab mafodotin)
- Blincyto (blinatumomab)
- bosentan
- Braftovi (encorafenib)
- Breyanzi (lisocabtagene maraleucel)
- Brilinta (ticagrelor)
Zynyz disease interactions
There are 4 disease interactions with Zynyz (retifanlimab) which include:
Report options
QR code containing a link to this page
More about Zynyz (retifanlimab)
- Zynyz consumer information
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
